DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR AZITHROMYCIN
Clinical Trials for Azithromycin
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00000617 | Azithromycin and Coronary Events Study (ACES) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | To determine whether treatment with azithromycin decreases the rate of coronary heart disease events among patients with stable documented coronary artery disease. |
| NCT00000641 | A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals. | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | To compare the effectiveness and toxicity of two combination drug treatment programs for the treatment of disseminated Mycobacterium avium infection in HIV seropositive patients. [Per 03/06/92 amendment: to evaluate the efficacy of azithromycin when given in conjunction with either ethambutol or clofazimine as maintenance therapy.] Disseminated M. avium infection is the most common systemic bacterial infection complicating AIDS in the United States. The prognosis of patients with disseminated M. avium is extremely poor, particularly when it follows other opportunistic infections or is associated with anemia. Test tube studies and clinical data indicate that the best treatment program may include clofazimine, ethambutol, a rifamycin derivative, and ciprofloxacin. Test tube and animal studies indicate that amikacin is a bactericidal (bacteria destroying) drug that works better when used with ciprofloxacin. Its role in treatment programs is a key issue because of toxicity and because it must be administered parenterally (by injection or intravenously). |
| NCT00000811 | A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 | This study compares 2 different treatments administered to try to prevent serious bacterial infections (such as pneumonia) in HIV-positive children. A combination of drugs (azithromycin plus atovaquone) will be compared to sulfamethoxazole-trimethoprim (SMX/TMP) alone. This study also evaluates the long-term safety and tolerance of these different drugs. SMX/TMP is a commonly prescribed drug for the prevention of bacterial infections. However, the combination of azithromycin and atovaquone may be safer and more effective than SMX/TMP. This study compares the 2 treatments. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Azithromycin
Condition Name
Clinical Trial Locations for Azithromycin
Trials by Country
Clinical Trial Progress for Azithromycin
Clinical Trial Phase
Clinical Trial Sponsors for Azithromycin
Sponsor Name
